Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheldon W Tobe

Showing results (111-120 of 154) with videos related to

Pageof 16
Sort By:
International Journal of Environmental Research and Public Health|March 6, 2014
Healthy food procurement policies and their impactMark L Niebylski, Tammy Lu, Norm R C Campbell, et al.
The Canadian Journal of Cardiology|April 2, 2015
A New Algorithm for the Diagnosis of Hypertension in CanadaLyne Cloutier, Stella S Daskalopoulou, Raj S Padwal, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 21, 2011
C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysisSimon D Roger, Francesco Locatelli, Rainer P Woitas, et al.
Diabetes, Obesity & Metabolism|November 13, 2020
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trialJeroen V Koomen, Jasper Stevens, George Bakris, et al.
The Canadian Journal of Cardiology|July 9, 2005
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of riskBrenda R Hemmelgarn, Finlay A McAllister, Martin G Myers, et al.
Diabetes, Obesity & Metabolism|December 17, 2016
Comparison of exposure response relationship of atrasentan between North American and Asian populationsHiddo J L Heerspink, Hirofumi Makino, Dennis Andress, et al.
Clinical Pharmacology and Therapeutics|December 18, 2020
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney DiseaseJeroen V Koomen, Jasper Stevens, George Bakris, et al.
CMAJ Open|April 28, 2017
The Cardiovascular Health in Ambulatory Care Research Team performance indicators for the primary prevention of cardiovascular disease: a modified Delphi panel studyJack V Tu, Laura C Maclagan, Dennis T Ko, et al.
Journal of the American Society of Nephrology : JASN|April 12, 2014
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathyDick de Zeeuw, Blai Coll, Dennis Andress, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 9, 2015
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic NephropathyDonald E Kohan, Hiddo J Lambers Heerspink, Blai Coll, et al.
Pageof 16

Showing results (111-120 of 154) with videos related to

Sort By:
Pageof 16
International Journal of Environmental Research and Public Health|March 6, 2014
Healthy food procurement policies and their impactMark L Niebylski, Tammy Lu, Norm R C Campbell, et al.
The Canadian Journal of Cardiology|April 2, 2015
A New Algorithm for the Diagnosis of Hypertension in CanadaLyne Cloutier, Stella S Daskalopoulou, Raj S Padwal, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 21, 2011
C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysisSimon D Roger, Francesco Locatelli, Rainer P Woitas, et al.
Diabetes, Obesity & Metabolism|November 13, 2020
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trialJeroen V Koomen, Jasper Stevens, George Bakris, et al.
The Canadian Journal of Cardiology|July 9, 2005
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of riskBrenda R Hemmelgarn, Finlay A McAllister, Martin G Myers, et al.
Diabetes, Obesity & Metabolism|December 17, 2016
Comparison of exposure response relationship of atrasentan between North American and Asian populationsHiddo J L Heerspink, Hirofumi Makino, Dennis Andress, et al.
Clinical Pharmacology and Therapeutics|December 18, 2020
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney DiseaseJeroen V Koomen, Jasper Stevens, George Bakris, et al.
CMAJ Open|April 28, 2017
The Cardiovascular Health in Ambulatory Care Research Team performance indicators for the primary prevention of cardiovascular disease: a modified Delphi panel studyJack V Tu, Laura C Maclagan, Dennis T Ko, et al.
Journal of the American Society of Nephrology : JASN|April 12, 2014
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathyDick de Zeeuw, Blai Coll, Dennis Andress, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 9, 2015
Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic NephropathyDonald E Kohan, Hiddo J Lambers Heerspink, Blai Coll, et al.
Pageof 16